CTOs on the Move

NeurogesX, Inc.

www.neurogesx.com

 
NeurogesX, Inc. is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Foster City, CA. To find more information about NeurogesX, Inc., please visit www.neurogesx.com
  • Number of Employees: 0-25
  • Annual Revenue: $50-100 Million
  • www.neurogesx.com
  • 2215 Bridgepointe Pkwy Ste 200
    Foster City, CA USA 94404-5067
  • Phone: 650.358.3300

Executives

Name Title Contact Details

Similar Companies

Care Axis

Care Axis is a Newcastle, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Stallion Technologies Inc

Stallion Technologies Inc is a Syracuse, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Allegiance Life

Allegiance Life is a Missoula, MT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Access Integrated Healthcare

Founded by Chief Executive Officer Sam Solakyan, Global Holdings, Inc. has excelled in its journey in becoming leaders in each of the industries it has a presence in. Their main responsibility lies in providing their clients with the most premiere level of service. More than just your typical holdings group, Global is a multifaceted company with financial assets and ownership in the radiology, pharmaceuticals, and medical billing and collections industries. Instead of merely buying and selling companies like other holdings groups, Global searches for the less desirable companies with hidden potential and applies its knowledge and expertise in the management field and aids in the recreation of a company that once was not.

Bioatla

BioAtla was founded in 2007 and employs deep expertise in protein engineering to develop better monoclonal antibody and other protein therapeutics. Our suite of proprietary technologies (protected by more than 70 issued patents and patent applications) has enabled us to develop dozens of novel therapeutic proteins for our partners and our own pipeline. We accelerate the process from target discovery to manufacturing and preclinical studies by creating drugs with more selective targeting, greater affinity, and more cost-efficient and predictable manufacturing. In the process we also create valuable, protectable IP that gives our partners significant competitive advantage. The culmination of our protein evolution technologies is our Conditionally Active Biologics (CAB)platform. Monoclonal antibodies or enzymes can be engineered for selective conditional activation, i.e. the protein`s functions are designed to modulate with changes in microphysical conditions (e.g., pH level, oxidation, temperature, pressure concentration, presence of certain ions, hydrophobicity and competing protein binding). Tumors and other kinds of diseased tissue give rise to unique localized conditions distinct from normal tissue. CAB designed monoclonal antibodies can be programmed to deliver an ADC payload and/or recruit the immune response to specific sites and conditions in the body.